Behavioral phenotyping of the MPTP mouse model of Parkinson's disease

Behavioural Brain Research

Volumn 125, Issue 1-2, 2001, Pages 109-125

  Sedelis, Marco ^a   Schwarting, Rainer K W ^b   Huston, Joseph P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Basal ganglia; Behavioral analysis; Dopamine; Motor deficits; MPTP; Neurotoxicity; Parkinson's disease, Review; Recovery

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DIETHYLDITHIOCARBAMIC ACID; MANEB; TROPOLONE;

AKINESIA; ANIMAL BEHAVIOR; BASAL GANGLION; BODY POSTURE; CONFERENCE PAPER; GAIT DISORDER; GENETIC MANIPULATION; MOTOR CONTROL; MOUSE STRAIN; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RIGIDITY; RISK FACTOR; TREMOR;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; MICE; MICE, INBRED STRAINS; MOTOR SKILLS; PARKINSONIAN DISORDERS; PHENOTYPE; SPECIES SPECIFICITY; SUBSTANTIA NIGRA;

EID: 0035829368     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(01)00309-6     Document Type: Conference Paper

References (141)

1. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex
2. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism
3. Atm-deficient mice: A paradigm of ataxia telangiectasia
4. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on striatal dopamine receptors in C57BL/6 mice
5. Evidence for an epileptogenic action of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine
6. The acute convulsant effect of MPTP is dependent on intracerebral MPP+
7. 1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway
8. MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area
9. The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice. Antagonism by monoamine oxidase inhibitors
10. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss
11. Nest-building behavior in two cerebellar mutant mice: Staggerer and weaver
12. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion
13. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice
14. Differential effects of deprenyl and MPTP on catecholamines and activity in BALB/c mice
15. Intrastriatal injection of 5,7-dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice
16. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice
17. Effects of MPTP on locomotor activity in mice
18. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate
19. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues
20. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse
21. Motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse
22. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease
23. Dopaminergic neurotoxicity of MPTP in the mouse: A murine model of parkinsonism
24. GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice
25. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo
26. Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo
27. The protective effects of PBN against MPTP toxicity are independent of hydroxyl radical trapping
28. MPTP-induced behavioural and biochemical deficits: A parametric analysis
29. Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice
30. MPTP-induced deficits in motor activity: Neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN)
31. Neonatal exposure to paraquat or MPTP induces permanent changes in striatum dopamine and behavior in adult mice
32. Effect of the competitive NMDA antagonist, CGP 40 116, and a low dose of L-Dopa on the motor activity deficit of MPTP-treated mice
33. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice
34. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice
35. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: Effects of glutamate antagonists
36. Effects of D1 and D2 agonists on spontaneous motor activity in MPTP treated mice
37. MPTP-induced hypoactivity in mice: Reversal by L-dopa
38. The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent
39. Amphetamine-induced circling behaviour in MPTP-lesioned mice
40. Behavioural effects of angiotensin II in the mouse following MPTP administration
41. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
42. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse
43. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1. Systemic administration
44. Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults
45. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse
46. Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse
47. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice
48. The MPTP-treated mouse as a model of parkinsonism: How good is it?
49. Evidence for a dissociation between MPTP-toxicity and tyrosinase activity based on congenic mouse strain susceptibility
50. The acute effect on levels of catecholamines and metabolites in brain of a single dose of MPTP in 8 strains of mice
51. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice
52. Activation and lateralization of sensorimotor field for perioral biting reflex by intranigral GABA agonist and by systemic apomorphine in the rat
53. Effect of the dopaminergic neurotoxin MPTP on cocaine-induced locomotor sensitization
54. Effects of beta-adrenergic blockers on drug-induced tremors
55. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives uptake by dopamine transporter and activity to induce parkinsonism
56. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations
57. Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice
58. Behavioral sequelae following MPTP administration in mice
59. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: A novel endogenous amine in mouse brain and parkinsonian CSF
60. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
61. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
62. MPTP-induced parkinsonism in humans: A review of the syndrome and observations relating to the phenomenon of tardive toxicity
63. Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine receptor system
64. Mesocorticolimbic dopaminergic network: Functional and regulatory roles
65. Neurotoxicity of MPTP and uptake of MPPT into dopamine and norepinephrine neurons in mice
66. Acute locomotor effects of MPTP in mice and relationships with dopaminergic systems
67. Acute ultrastructural and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice
68. No apparent difference in the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the sympathetic system in NMRI and C57 BL/6 mice
69. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
70. Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: A possible causative protoxin in idiopathic Parkinson's disease
71. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion
72. Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys
73. MPTP-induced parkinsonism in mini-pigs: A behavioral, biochemical, and histological study
74. Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium
75. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
76. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
77. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice
78. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice
79. Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa
80. A simple quantitative bradykinesia test in MPTP-treated mice
81. MPTP-induced parkinsonian model in mice biochemistry, pharmacology and behavior
82. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test
83. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopamine D2 receptor hypersensitivity in the mouse is transient
84. Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) in mouse brain
85. MPTP-induced decrease in motor activity in two strains of mice: Its reversal by different monoamine oxidase inhibitors (MAOIs)
86. Climbing behavior induced by apomorphine in mice: A simple test for the study of dopamine receptors in striatum
87. Mechanisms of MPTP toxicity
88. The parkinsonian toxin MPTP: Action and mechanism
89. Acute and long term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in tests of nociception in mice
90. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice
91. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism
92. The catalepsy test
93. MPTP-induced parkinsonism acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment
94. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism
95. Amphetamine induces hypermotility in MPTP-lesioned mice
96. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: Analysis of functional deficits, recovery and treatments
97. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae
98. Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease
99. Evidence for resistance to MPTP in C57BL/6 × BALB/c F1 hybrids as compared with their progenitor strains
100. MPTP susceptibility in the mouse: Behavioral, neurochemical and histological analysis of gender and strain differences
101. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease
102. Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse
103. Reduction of dopamine uptake and cocaine binding in mouse striatum by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
104. Preferences of individually housed TO strain laboratory mice for loose substrate or tubes for sleeping
105. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP
106. Handedness in rats: Blockade of reaching behavior by unilateral 6-OHDA injections into substantia nigra and caudate nucleus
107. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine
108. The weaver mutant mouse as a model of nigrostriatal dysfunction
109. A comparison between house mouse lines selected for attack latency or nest-building evidence for a genetic basis of alternative behavioral strategies
110. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism
111. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
112. Differences in pre- and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity
113. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: A model for Parkinson's disease
114. MPTP-treated mice: A useful model for Parkinson's disease?
115. Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57 BL/6 mice
116. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice
117. Behavioral and biochemical changes following acute administration of MPTP and MPP+
118. Maneb enhances MPTP neurotoxicity in mice
119. Cognitive changes in mice following moderate MPTP exposure
120. Effect of chronic administration of magnesium sulfate on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice
121. 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities
122. The neuropsychology of Parkinson's disease
123. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)
124. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
125. Neuroanatomical substrate of behavioural impairment in weaver mutant mice
126. Age-related changes in locomotor behavior induced by MPTP in rats
127. L-dopa reverses the effects of MPP+ toxicity
128. Increased sensitivity of mice to tremorogenic agents following MPP+
129. Dopamine receptor plasticity following MPTP-induced nigrostriatal lesions in the mouse
130. Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice
131. Dissociation between biochemical and behavioral recovery in MPTP-treated mice
132. Dopamine receptors and sensorimotor behavior in MPTP-treated mice
133. Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice
134. Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice
135. Dopamine D1 receptor and dopamine D2 receptor binding activity changes during chronic administration of nicotine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice
136. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice
137. Amine accumulation, catecholamine depletion and motor impairment in Macaca fasicularis and the C-57 black mouse after MPTP administration
138. Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
139. Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications
140. Animal models of parkinsonism using selective neurotoxins: Clinical and basic implications
141. Selective lesion of the nigrostriatal dopaminergic pathway by MPTP and acetaldehyde or diethyldithiocarbamate